Morphosys: Setzen auf marktreife Partnerprojekte und dicke Meilensteine (Seite 1846)

[butch.]

BlackRock oder Charttechnik oder beides oder was?
Schön auf jeden Fall.

[Tigerslady]

abwärtstrend beendet, auf gehts Richtung 117, vorerst, diese woche sollte generell grün werden, heute noch ein paar Leute rausspülen, dann nordwärts

[inkogno]

Antwort auf Beitrag Nr.: 65.056.416 von Ditjg am 11.09.20 17:16:16

Zitat von Ditjg: Ein Onkologe ist ein hochspezialisierter Arzt, kämpft jeden Tag um Leben und weiß, was er tut. Wenn man so diskutiert, wird man immer ein Kontra finden.

Mit Monjuvi/Tafasitamab soll explizit auch das Community Setting und nicht nur hochspezialisierte Onkologie-Ärzte und -Center angesprochen werden. Genau das sollte ja der Trumpf von Monjuvi sein - der lokale Arzt (mit Spezialisierung) kann es verschreiben. Ein Onkologe kann nur den Überblick über die Vielzahl Therapien behalten, wenn er sich auf ganz wenige Krebsarten spezialisiert. Wer da Zweifel hat, sollte sich die Kompendien bei NCCN zu allen Krebsarten mal zu Gemüte führen. Und dabei bedenken, dass sich das alle paar Monate ändert.

[DaxProPlayer]

Der Abwärtstrend sollte nun nach oben aufgelöst werden.

[archie1974]

Antwort auf Beitrag Nr.: 65.057.940 von Caldo am 11.09.20 19:29:59

Zitat von Caldo: CSJ117

ERS INTERNATIONAL CONGRESS 2020

Late Breaking Abstract
Efficacy of CSJ117 on allergen-induced asthmatic responses in mild atopic asthma patients

Gail Gauvreau, Jens Hohlfeld, Louis-Philippe Boulet, Donald Cockcroft, Beth Davis, J Mark Fitzgerald, Stephanie Korn , Oliver Kornmann , Richard Leigh, Irvin Mayers, Hendrik Watz, Sarah Grant, Monish Jain , Maciej Cabanski , Peter Pertel , Ieuan Jones , Jean Lecot , Paul O'Byrne

Introduction: CSJ117 is a potent neutralizing antibody fragment against human Thymic stromal lymphopoietin (TSLP), formulated as a PulmoSol™ engineered powder in hard capsules for delivery to the lungs via dry powder inhaler.

Methods: In this double-blind, placebo-controlled study, 28 mild, atopic asthmatics meeting elibility criteria were randomized to receive 4mg CSJ117 (n = 15) or placebo (n = 13) inhaled daily for 12 weeks. Allergen inhalation challenge (AIC) was conducted at screening, day 42 and day 84. The primary efficacy variable was the late asthmatic response (LAR), measured 3 to 7 hours after AIC at day 84. Other outcomes included the early asthmatic response (EAR) measured within 2 hours after AIC, fractional exhaled nitric oxide (FeNO) level, and sputum eosinophils. Data were analyzed using repeated measures ANCOVA (ß=10%) and one-sided tests (a=10%).

Results: CSJ117 attenuated allergen-induced LAR and EAR at day 84. The time-adjusted AUC percentage decrease and the maximum decrease in FEV1 from pre-AIC were lower in the CSJ117 group compared to placebo (4.20% vs 11.38%, p = 0.008, and 9.28% vs 17.70%, P=0.029, during LAR; 12.83% vs 17.09%, P = 0.097, and 25.48% vs 30.90%, P = 0.105, during EAR). CSJ117 significantly attenuated the allergen-induced increase in % sputum eosinophils after AIC on day 84. CSJ117 significantly reduced FeNO before AIC at Day 83, but not the allergen-induced change.

Conclusion: CSJ117 reduced allergen-induced bronchoconstriction and sputum eosinophilia, and pre challenge FeNO levels. These findings demonstrate CSJ117's ability to attenuate airway inflammation in allergic asthmatics and support further studies as an inhaled anti-TSLP.

https://erscongress.org/

Phase 2b mit 625 Patienten startet am 25. September, Ergebnisse werden Ende 2021 erwartet.

https://clinicaltrials.gov/ct2/show/NCT04410523

[Caldo]

Guselkumab

10.09.2020 | Original Research Article

Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study


Results
The proportions of guselkumab-treated patients who achieved and maintained designated clinical responses at weeks 100 and 204, respectively, were as follows: at least a 75% improvement in Psoriasis Area and Severity Index from baseline (PASI 75): 94.1% and 92.3%; PASI 90: 79.1% and 79.7%; PASI 100: 48.4% and 51.0%; Investigator's Global Assessment (IGA) score of 0/1: 83.1% and 81.9%; IGA score of 0: 52.7% and 52.7%; Dermatology Life Quality Index score of 0/1: 70.2% and 69.1%; Psoriasis Symptoms and Signs Diary (PSSD) symptom score of 0: 35.7% and 39.7% ... No new safety signals were identified.

Conclusions
High efficacy levels were maintained from week 100 through to week 204 with continuous guselkumab treatment, across multiple endpoints, in VOYAGE 2. Guselkumab was well tolerated.

https://www.springermedizin.de/maintenance-of-response-throu…

[Caldo]

Guselkumab

Guselkumab for hidradenitis suppurativa in a patient with concomitant Crohn's disease:
Report and systematic literature review of effectiveness and safety

First published: 10 September 2020


Abstract

Guselkumab appears to be safe and effective in the treatment of patients with HS, who do not respond to adalimumab and other systemic therapies. Guselkumab can be used in patients with comorbid Crohn's disease.

INTRODUCTION

We present a case of a 25-year-old man with hidradenitis suppurativa (HS) and comorbid Crohn's disease successfully treated with guselkumab. After 7 months of treatment, the patient experienced an objective improvement and showed remarkable symptom relief ...

https://onlinelibrary.wiley.com/doi/full/10.1002/ccr3.3090

[Caldo]

CSJ117

ERS INTERNATIONAL CONGRESS 2020

Late Breaking Abstract
Efficacy of CSJ117 on allergen-induced asthmatic responses in mild atopic asthma patients

Gail Gauvreau, Jens Hohlfeld, Louis-Philippe Boulet, Donald Cockcroft, Beth Davis, J Mark Fitzgerald, Stephanie Korn , Oliver Kornmann , Richard Leigh, Irvin Mayers, Hendrik Watz, Sarah Grant, Monish Jain , Maciej Cabanski , Peter Pertel , Ieuan Jones , Jean Lecot , Paul O'Byrne

Introduction: CSJ117 is a potent neutralizing antibody fragment against human Thymic stromal lymphopoietin (TSLP), formulated as a PulmoSol™ engineered powder in hard capsules for delivery to the lungs via dry powder inhaler.

Methods: In this double-blind, placebo-controlled study, 28 mild, atopic asthmatics meeting elibility criteria were randomized to receive 4mg CSJ117 (n = 15) or placebo (n = 13) inhaled daily for 12 weeks. Allergen inhalation challenge (AIC) was conducted at screening, day 42 and day 84. The primary efficacy variable was the late asthmatic response (LAR), measured 3 to 7 hours after AIC at day 84. Other outcomes included the early asthmatic response (EAR) measured within 2 hours after AIC, fractional exhaled nitric oxide (FeNO) level, and sputum eosinophils. Data were analyzed using repeated measures ANCOVA (ß=10%) and one-sided tests (a=10%).

Results: CSJ117 attenuated allergen-induced LAR and EAR at day 84. The time-adjusted AUC percentage decrease and the maximum decrease in FEV1 from pre-AIC were lower in the CSJ117 group compared to placebo (4.20% vs 11.38%, p = 0.008, and 9.28% vs 17.70%, P=0.029, during LAR; 12.83% vs 17.09%, P = 0.097, and 25.48% vs 30.90%, P = 0.105, during EAR). CSJ117 significantly attenuated the allergen-induced increase in % sputum eosinophils after AIC on day 84. CSJ117 significantly reduced FeNO before AIC at Day 83, but not the allergen-induced change.

Conclusion: CSJ117 reduced allergen-induced bronchoconstriction and sputum eosinophilia, and pre challenge FeNO levels. These findings demonstrate CSJ117's ability to attenuate airway inflammation in allergic asthmatics and support further studies as an inhaled anti-TSLP.

https://erscongress.org/

[Ditjg]

Antwort auf Beitrag Nr.: 65.054.934 von riverstar_de am 11.09.20 15:14:39

Zitat von riverstar_de:

Zitat von yok: Die Ärzte sind ja auch nicht ganz dumm, sondern suchen selbst aus, was sie denken, was ihren Patienten am besten helfen kann.

ich weiß ja nicht, wie Deine Erfahrungen mit Ärzten sind, aber ich habe da schon etliche erlebt, die nicht so durchsehen. Ob die dann immer das beste/neueste Produkt kennen? Mann kann es nur hoffen.

Ein Onkologe ist ein hochspezialisierter Arzt, kämpft jeden Tag um Leben und weiß, was er tut.
Wenn man so diskutiert, wird man immer ein Kontra finden.

[yok]

Ich hab nen super Arzt... und ich sage ihm, wenn ich was bestimmtes haben will. Ich kann nur jedem, der mit seinen Ärzten unzufrieden ist, raten zu wechseln. Einen Hämatologen, der nicht vom neuesten DLBCL treatment gehört hat, kann ich mir nicht recht vorstellen. Wer streng nach Richtlinien verfährt, kann kein Pola als 2nd line geben. Und dann GemOx, eine zweite harte Letzte-Hoffnung-Chemo verschreiben, wenn eine neue Kombo mit so guten Wirksamkeits- und Sicherheitsdaten verfügbar ist?